SETX and colon adenocarcinoma: Furthermore, a study analyzing the non-neurological clinical features of 32 ALS4 patients harboring the L389S or E385K gain of function mutations of SETX revealed that five ALS4 patients have benign neoplasia of the colon (colonic polyps) and two display malignant lesions (adenocarcinoma of the colon) [100].